BioSpace News Archive

Fennec Pharmaceuticals Inc. announced that the nominees listed in the management proxy circular dated May 14, 2021 for the Annual General Meeting of Shareholders were elected as directors of the Company at the Annual General Meeting of Shareholders held in Irvine, California and online on June 29, 2021.

Intellia Therapeutics, Inc., a leading clinical-stage genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo and ex vivo, announced the pricing of an underwritten public offering of 4,137,931 shares of its common stock at a public offering price of $145.00 per share.

Increased awareness about mental health disorder and improving treatment methods for the same would drive market growth.

Advancements in healthcare sector, and growing awareness related to assisted reproductive technology.

Advancements in technology, rising use of meshes in the surgeries, and increasing geriatric population would drive market growth.

Government funding for preparedness of bioterrorist attacks is a key factor that would drive global market growth.

Health Canada is updating the product monograph—or label—for the AstraZeneca and COVISHIELD COVID-19/ vaccines to add capillary leak syndrome as a potential side effect, with a warning for patients with a history of capillary leak syndrome to not get the AstraZeneca or COVISHIELD COVID-19 vaccine.

Yield10 Bioscience, Inc. today announced two new hires. Tichafa Munyikwa, Ph.D. has been appointed Director of Regulatory Affairs.

Explosion of innovation expected with Pharmapack Awards now open for entries.

DarioHealth Corp. (Nasdaq: DRIO), a leader in the global digital therapeutics (DTx) market, presented new clinical research today at the American Diabetes Association (ADA) 81st Scientific Sessions, the premier diabetes conference for cutting-edge research and advances in diabetes care.